Zhejiang Huakang Pharmaceutical Co., Ltd.SSE: 605077

(605077)"Zhejiang Huakang Pharmaceutical Co., Ltd."Report for Q3 2026

· Issued by Zhejiang Huakang Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 605077 · · 12 pages · Chinese

Summary by 6ix AI

The report indicates a significant decline in profit and earnings compared to the same period last year, with total revenue and net profit both experiencing substantial decreases. The company attributes these declines to increased competition and changes in sales strategy, particularly in the liquid product segment. The report also includes unaudited financial statements and highlights the company's commitment to transparency and accuracy in its disclosures.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Zhejiang Huakang Pharmaceutical Co., Ltd. on 6ix

Earlier from Zhejiang Huakang Pharmaceutical

Later from Zhejiang Huakang Pharmaceutical

All Zhejiang Huakang Pharmaceutical news releases